LY3154885 manufacturers
- LY3154885
-
- $2140.00
-
2026-05-11
- CAS:2379422-72-5
- Purity:
- Supply Ability: 10g
|
| | LY3154885 Basic information |
| Product Name: | LY3154885 | | Synonyms: | LY3154885;Ethanone, 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3,4-dihydro-3-(hydroxymethyl)-1-methyl-5-(1-methyl-1H-pyrazol-4-yl)-2(1H)-isoquinolinyl]-;2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-1-methyl-5-(1-methyl-4-pyrazolyl)-3,4-dihydro-1H-isoquinolin-2-yl]ethanone | | CAS: | 2379422-72-5 | | MF: | C23H23Cl2N3O2 | | MW: | 444.35 | | EINECS: | | | Product Categories: | | | Mol File: | 2379422-72-5.mol |  |
| | LY3154885 Chemical Properties |
| Boiling point | 668.5±55.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | pka | 14.58±0.10(Predicted) |
| | LY3154885 Usage And Synthesis |
| Uses | LY3154885 is an orally active dopamine D1 receptor positive allosteric modulator (PAM). LY3154885 has an improved agent-agent interactions (DDI) risk profile[1]. | | References | [1] Junliang Hao, et al. Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile. J Med Chem. 2022 Mar 10;65(5):3786-3797. DOI:10.1021/acs.jmedchem.1c01887 |
| | LY3154885 Preparation Products And Raw materials |
|